Results 61 to 70 of about 34,942 (245)
Ziyad Alrabiah, Wajid Syed, Salmeen D Babelghaith, Mohamed N Al Arifi Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi ArabiaCorrespondence: Wajid Syed, Email wali@ksu.edu.saBackground and Aims: It is ...
Alrabiah Z +3 more
doaj
Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods
To try to predict an individual’s drug response using genetic data, most studies have used traditional polygenic risk score (PRS) methods. Here, the authors develop a pharmacogenomics-specific PRS method, which can improve drug response prediction and ...
Song Zhai +3 more
doaj +1 more source
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa +21 more
wiley +1 more source
Pharmacogenomics In Pharmacy Practice: Current Perspectives
Hazem Elewa, Ahmed Awaisu College of Pharmacy, Qatar University Health, Qatar University, Doha, QatarCorrespondence: Hazem ElewaCollege of Pharmacy, Qatar University Health, Qatar University, P.O.
Elewa H, Awaisu A
doaj
Background: As pharmacogenomics (PGx), a component of genetics/genomics and precision medicine, gains traction in the clinical setting, education of health care providers and health professions students must be made broadly available to improve ...
David F Kisor, Christopher L Farrell
doaj +1 more source
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind +7 more
wiley +1 more source
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton +8 more
wiley +1 more source
Paul Y Takahashi,1 Euijung Ryu,2 Suzette J Bielinski,3 Matthew Hathcock,2 Gregory D Jenkins,2 James R Cerhan,3 Janet E Olson3 1Division of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of ...
Takahashi PY +6 more
doaj
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan +24 more
wiley +1 more source

